Women's Health
Roche Diagnostics is committed to Women’s Health in Australia
Fundamental inequities that exist within health systems can have a detrimental effect on the diagnosis, treatment and care that ALL WOMEN receive. Roche strives for a worldwide transformation of Women’s Health by raising awareness about the gaps that exist and collaborating with stakeholders across the ecosystem to address the barriers that prevent women from receiving the healthcare they need.
Historically, women have often been underrepresented in clinical research, leading to a misunderstanding of their unique health needs. Although participation in clinical trials has improved, more work is needed to systematically analyse and report data through a sex and gender lens. Organisations across the healthcare industry must prioritise these considerations throughout the entire research and development lifecycle to enhance Women's Health outcomes.
Women’s Health should not be viewed narrowly but rather through a holistic lens that considers their complete experiences. Roche believes that a woman-centric approach can empower women to make informed healthcare decisions, leading to improved outcomes and equitable care tailored to their individual needs.
Women account for half of humanity, however:
5%
Share of assets in the current healthcare pipeline are focused on female conditions.1
56%
Proportion of diseases that primarily affect women are being underfunded.2
74%
Of clinical trials do not report outcomes by sex.+3
Women face unmet needs…resulting in them facing worse health outcomes than men.
Around the world women experience their health differently than men.
21% of women who visited a doctor in the previous two years said a healthcare professional has dismissed their concerns or didn’t believe they were telling the truth, versus only 12% of men.5
Women are less likely to be prescribed painkillers than men even when they are experiencing similar levels of pain.6
Women are 75% more likely to use digital tools for healthcare than men.7
Globally women face worse health outcomes than men.
Women spend 25% more time of their lives in unhealthy conditions versus men.13
Women experience more adverse events than men, and those adverse events are more serious in women.14
Pregnancy increases the risk factor of diseases such as diabetes and in turn Diabetic Retinopathy.15
Our commitment: With her today. With her for life.
Our Women’s Health offering in Diagnostics.
Roche Diagnostics provides innovative diagnostic tests and solutions to help assess risk, identify disease, and monitor patients, with specific solutions intended to meet the unique needs of women throughout the different stages of life.
Topic areas include cervical cancer screening, breast health, ovarian cancer, fertility, pregnancy care, non-invasive prenatal testing (NIPT), sexual health, as well as other disease areas such as bone health, where women may have different signs, symptoms or incidence rates.
We’ve already tested over 75 million women globally….
Our innovative solutions in Women’s Health give HCPs the ability to provide the right treatment at the right time, offering confidence that only Roche Diagnostics can deliver.
Breast cancer: Over 6.5 million women received predictive diagnostics tests to aid in breast cancer treatment decisions (HER2, ER and PR).
Cervical cancer: Over 22 million women gained information about risk from Roche’s cervical cancer portfolio for screening and disease management.
Ovarian cancer: Ovarian cancer is the 8th overall cause for cancer death in women, representing 5% of all cancer deaths in women.16
Endometrial: Endometrial cancer is the 6th most common cancer in women worldwide.17
STI Screening: There are more than one million sexually transmitted infections (STIs) acquired every day worldwide.18
Bone Health: It is estimated that an osteoporotic fracture occurs every three seconds and more than 200 million women are affected by osteoporosis worldwide.19
Fertility and Pregnancy Care
AMH Plus: Over one million women explored factors related to AMH/AMH Plus as an indication of ovarian reserve in the quest to potentially build a family.
NIPT: Approximately half a million expectant mothers were given accurate information about their baby.
Preeclampsia: Approximately half a million pregnant women were properly managed with preeclampsia ratio tests.
For our team, focusing on Women’s Health is improving healthcare in conditions that present differently in women or predominantly impact them.
Every woman benefits from tailored and equitable healthcare across all stages of her life.
With a global team leading Roche's Women's Health strategy, we are taking a more holistic approach to Women's Health and increasingly embedding this focus area across different parts of the business to maximise the impact and difference we can make for women around the world and here in Australia.
Roche Diagnostics will be with her today and with her for life.
?wid=335&hei=188&fmt=png-alpha)
Rebecca Steer
National Sales Manager
Molecular Laboratory
?wid=335&hei=188&fmt=png-alpha)
Yu Wooi Ching
National Sales Manager
Pathology Laboratory
?wid=335&hei=188&fmt=png-alpha)
Martin Leonard
National Sales Manager
Core Laboratory
?wid=335&hei=188&fmt=png-alpha)
Dr Lauren Harper
Medical Affairs Lead
?wid=335&hei=188&fmt=png-alpha)
Maegan Kerr
Reagent Sales & Applications Specialist
?wid=335&hei=188&fmt=png-alpha)
Janet Thomson
Solutions Manager
Tissue Diagnostics
?wid=335&hei=188&fmt=png-alpha)
Nina Clifford
Solutions Manager
Molecular Diagnostics
?wid=335&hei=188&fmt=png-alpha)
Hiren Sheth
Solutions Manager
Sequencing
?wid=335&hei=188&fmt=png-alpha)
Victoria Kirby
Disease Area Lead
?wid=335&hei=188&fmt=png-alpha)
Shona Reynolds
Disease Area Lead
Get in touch to find out more about our commitment to Women's Health
This page is provided as a contact service and does not replace the advice of a physician. Roche cannot respond to questions about general medical information or questions regarding your personal medical condition. Medications and diagnostics products can not be directly ordered through this website. Please note that we do not respond to form letters or e-mail campaigns.